Article
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis.
JCI insight - 20 Dec 2024
Yang Wang, Zhang Ming, Zhang Tian-Xing, Liu Jia-Hui, Hao Man-Wei, Yan Xu, Gao Haicheng, Lei Qun-Ying, Cui Jiuwei, Zhou Xin
Abstract excerpt
KRAS mutations are frequent in various human cancers. The development of selective inhibitors targeting KRAS mutations has opened a new era for targeted therapy. However, intrinsic and acquired resistance to these inhibitors remains a major challenge. Here, we found that cancer cells resistant to KRAS G12C inhibitors also display cross-resistance to other targeted therapies, such as inhibitors of RTKs or SHP2....
Topics
- Humans
- Proto-Oncogene Proteins p21(ras)
- Apoptosis
- Drug Resistance, Neoplasm
- Transcription Factors
- YAP-Signaling Proteins
- TOR Serine-Threonine Kinases
- Cell Line, Tumor
- Adaptor Proteins, Signal Transducing
- Signal Transduction